Cipher Pharmaceuticals Future Growth
Future criteria checks 2/6
Cipher Pharmaceuticals is forecast to grow earnings and revenue by 7.3% and 9.9% per annum respectively. EPS is expected to grow by 6.3% per annum. Return on equity is forecast to be 13.1% in 3 years.
Key information
7.3%
Earnings growth rate
6.32%
EPS growth rate
| Pharmaceuticals earnings growth | 58.6% |
| Revenue growth rate | 9.9% |
| Future return on equity | 13.13% |
| Analyst coverage | Low |
| Last updated | 07 Nov 2025 |
Recent future growth updates
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 09Recent updates
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Nov 09These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Oct 10Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
Aug 29We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
May 16Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
May 09Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Apr 28
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Dec 13Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Nov 14With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Nov 12Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 09There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Mar 23Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
Mar 22Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
May 14Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)
May 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 67 | 21 | N/A | 32 | 2 |
| 12/31/2026 | 56 | 17 | N/A | 21 | 3 |
| 12/31/2025 | 51 | 17 | 0 | 30 | 3 |
| 9/30/2025 | 50 | 17 | 30 | 30 | N/A |
| 6/30/2025 | 48 | 12 | -59 | 21 | N/A |
| 3/31/2025 | 40 | 9 | -59 | 21 | N/A |
| 12/31/2024 | 33 | 12 | -60 | 20 | N/A |
| 9/30/2024 | 26 | 16 | -67 | 13 | N/A |
| 6/30/2024 | 22 | 23 | 17 | 17 | N/A |
| 3/31/2024 | 22 | 23 | 14 | 14 | N/A |
| 12/31/2023 | 21 | 20 | 16 | 16 | N/A |
| 9/30/2023 | 21 | 32 | 15 | 15 | N/A |
| 6/30/2023 | 20 | 28 | 13 | 13 | N/A |
| 3/31/2023 | 20 | 27 | 13 | 13 | N/A |
| 12/31/2022 | 21 | 27 | 11 | 11 | N/A |
| 9/30/2022 | 22 | 10 | 15 | 15 | N/A |
| 6/30/2022 | 21 | 8 | 11 | 11 | N/A |
| 3/31/2022 | 22 | 9 | 11 | 11 | N/A |
| 12/31/2021 | 22 | 8 | 14 | 14 | N/A |
| 9/30/2021 | 22 | 5 | 14 | 14 | N/A |
| 6/30/2021 | 23 | 6 | 12 | 12 | N/A |
| 3/31/2021 | 21 | 3 | 11 | 11 | N/A |
| 12/31/2020 | 22 | 4 | 11 | 12 | N/A |
| 9/30/2020 | 21 | 7 | 7 | 7 | N/A |
| 6/30/2020 | 22 | 3 | 10 | 11 | N/A |
| 3/31/2020 | 23 | 4 | 11 | 12 | N/A |
| 12/31/2019 | 22 | 3 | 7 | 8 | N/A |
| 9/30/2019 | 23 | -1 | 6 | 8 | N/A |
| 6/30/2019 | 22 | 2 | N/A | 6 | N/A |
| 3/31/2019 | 23 | 3 | N/A | 2 | N/A |
| 12/31/2018 | 23 | 1 | N/A | 8 | N/A |
| 9/30/2018 | 28 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 34 | 9 | N/A | 18 | N/A |
| 3/31/2018 | 37 | 11 | N/A | 19 | N/A |
| 12/31/2017 | 40 | 11 | N/A | 13 | N/A |
| 9/30/2017 | 34 | 7 | N/A | 11 | N/A |
| 6/30/2017 | 32 | 5 | N/A | 9 | N/A |
| 3/31/2017 | 31 | 1 | N/A | 10 | N/A |
| 12/31/2016 | 30 | 4 | N/A | 11 | N/A |
| 9/30/2016 | 33 | 6 | N/A | 8 | N/A |
| 6/30/2016 | 34 | 2 | N/A | 7 | N/A |
| 3/31/2016 | 34 | 1 | N/A | 7 | N/A |
| 12/31/2015 | 34 | 2 | N/A | 8 | N/A |
| 9/30/2015 | 32 | 3 | N/A | 12 | N/A |
| 6/30/2015 | 30 | 13 | N/A | 16 | N/A |
| 3/31/2015 | 30 | 18 | N/A | 19 | N/A |
| 12/31/2014 | 29 | 19 | N/A | 25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPH's forecast earnings growth (7.3% per year) is above the savings rate (2.8%).
Earnings vs Market: CPH's earnings (7.3% per year) are forecast to grow slower than the Canadian market (11.6% per year).
High Growth Earnings: CPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: CPH's revenue (9.9% per year) is forecast to grow faster than the Canadian market (4.6% per year).
High Growth Revenue: CPH's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CPH's Return on Equity is forecast to be low in 3 years time (13.1%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 14:57 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |
| David Novak | Cormark Securities Inc. |